TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S.
20.01% operating margin is above average. ROIC at 14.14%.
Revenue up 87.3% YoY with margins expanding 7.3pp.
Negative free cash flow of -$25M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$700M
▲ +87.3% YoY
Net Income (TTM)
$462M
▲ +1812.4% YoY
Op. Margin
21.35%
▲ +7.3pp YoY
ROIC
13.02%
▲ +3.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$14M
▲ +38.4% YoY
Op. Cash Flow (TTM)
-$14M
▲ +38.9% YoY
Net Debt
$239M
Cash & Equiv.
$514M
5Y CAGR: +426.7%
Continue Research